John Todd Mitchell

CLO John Todd Mitchell sells 80,152 shares for $3,023,706.29 via scheduled 10b5-1 plan (adopted 2025-12-08); retains 803,566 shares post-sale

John Todd Mitchell, Chief Legal Officer & Secretary, executed 4 separate sales totaling 80,152 shares for $3,023,706.29 on 2026-05-15 and 2026-05-18, reducing his holdings from 883,718 shares to 803,566 shares (-9.1%). This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, meaning the sales were scheduled in advance rather than discretionary. The blended average sale price of $37.72 compares favorably to the current stock price of $36.72 (-14.8% from the 52-week high of $43.08); Mitchell's prior open-market sell activity showed average 90-day returns of +29.4%, though that cross-ticker result does not directly predict outcomes at PACS. The company itself shows strong fundamentals with quarterly revenue of $1,420,494,000.00, net income of $80,695,000.00, and annual revenue growth of +29.3%, with a P/E of 23.84 and market cap of $5,811,761,646.72.

Chief Legal Officer sold 159,556 shares (17.4% reduction) at $29.89, reducing holdings from 915,392 to 755,836 shares in fast-growing $5.0B healthcare company.

Mitchell John Todd sold 159,556 shares valued at $4,768,378.93 on 2025-11-24 at $29.89, reducing his stake by 17.4% to 755,836 shares remaining. The transaction occurred while PACS stock trades near its 52-week high of $32.16 and the company demonstrates strong fundamentals: 31.4% annual revenue growth, $1.3B quarterly revenue, $52.4M net income, and a market cap of $5.0B. The 30-day price appreciation of 155.2% and 90-day appreciation of 177.0% preceded the sale, and the transaction price of $29.89 sits 7.1% below the current $32.16 price. A C-suite officer's $4.8M equity reduction warrants monitoring given the company's strong recent operational momentum and valuation multiples (P/E 29.78), though the size of remaining holdings (755,836 shares) indicates continued substantial stakes in the company.